Skip to content

Onconova Therapeutics (NASDAQ: ONTX) Decreased to Hold at Zacks Investment Research

Onconova (NASDAQ: ONTX) was reduced by  from a “purchase” rating to a “hold” rating in a research note issued to investors on Thursday, records.

According to Zacks, “Onconova Therapeutics, Inc. runs as a clinical-stage biopharmaceutical business. It focuses on discovering and creating small particle drug candidates to treat cancer. The Business‘s products under various stages of advancement consist of Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “

Numerous other equities research experts additionally lately commented on the firm. Noble Financial editioned a “buy” rating as well as released a $11.00 rate goal on shares of Onconova Therapeutics in a record on Thursday, September 23rd. Guggenheim dropped their price target on Onconova Therapeutics from $29.00 to $12.00 as well as set a “buy” ranking on the stock in a research note on Tuesday, September 28th.

NASDAQ: ONTX opened at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 and a twelve month high of $28.95. Business has a 50 day moving typical cost of $2.90 as well as a two-hundred day relocating average cost of $4.16. The business has a market cap of $46.76 million, a P/E proportion of -1.82 and also a beta of 1.67.

Onconova Therapeutics (NASDAQ: ONTX) last released its quarterly profits outcomes on Thursday, November 11th. The biopharmaceutical business reported ($ 0.22) incomes per share for the quarter, covering analysts’ consensus estimates of ($ 0.33) by $0.11. Onconova Therapeutics had an unfavorable return on equity of 59.78% as well as an adverse net margin of 8,294.27%. The firm had earnings of $0.06 million throughout the quarter, compared to the agreement price quote of $0.06 million. During the same quarter in the prior year, the firm posted ($ 0.45) EPS. As a group, research experts anticipate that Onconova Therapeutics will publish -1.18 EPS for the existing year.

A variety of hedge funds have actually just recently dealt shares of ONTX. GSA Capital Allies LLP acquired a brand-new placement in Onconova Therapeutics during the 3rd quarter worth $922,000. Hudson Bay Resources Administration LP purchased a new position in shares of Onconova Therapeutics in the 3rd quarter worth $635,000. Pura Vida Investments LLC bought a brand-new placement in shares of Onconova Therapeutics in the 3rd quarter worth $575,000. CVI Holdings LLC got a brand-new position in shares of Onconova Therapeutics in the third quarter worth $493,000. Finally, Dimensional Fund Advisors LP got a new placement in shares of Onconova Therapeutics in the second quarter worth $509,000. Hedge funds as well as various other institutional financiers have 13.36% of the company’s stock.

About Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical firm, which engages in the recognition as well as growth of oncology therapeutics. It focuses on finding and also developing tiny molecule medicine prospects to deal with cancer. The firm was founded by Ramesh Kumar and also E. Premkumar Reddy on December 22, 1998 and also is headquartered in Newtown, PA

. Get a totally free copy of the Zacks research record on Onconova Therapeutics (ONTX).

For more information concerning research offerings from Zacks Investment Research, go to

This instantaneous information alert was generated by narrative science technology and economic information from Market in order to supply viewers with the fastest and most accurate coverage. This tale was assessed by Market’s editorial group before publication. 



Before you take into consideration Onconova Therapeutics, you’ll want to hear this.

Market keeps an eye on Wall Street’s premier as well as finest performing research experts as well as the stocks they advise to their customers daily. Market has actually identified the 5 stocks that top analysts are quietly whispering to their customers to buy now prior to the more comprehensive market catches on … and Onconova Therapeutics wasn’t on the checklist.

While Onconova Therapeutics currently has a “Buy” rating among experts, premier experts think these five stocks are better purchases.